CytomX Therapeutics Inc. (NASDAQ:CTMX) rose 5.1% during trading on Tuesday . The stock traded as high as $11.89 and last traded at $11.71, with a volume of 61,561 shares traded. The stock had previously closed at $11.14.

CTMX has been the subject of several research analyst reports. Oppenheimer Holdings Inc. restated a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $19.00.

The company’s market capitalization is $404.97 million. The stock’s 50 day moving average price is $10.70 and its 200-day moving average price is $11.61.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.02. Equities research analysts expect that CytomX Therapeutics Inc. will post ($1.59) EPS for the current year.

In other news, Director Timothy M. Shannon sold 48,427 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $10.07, for a total transaction of $487,659.89. Following the completion of the sale, the director now directly owns 134 shares of the company’s stock, valued at approximately $1,349.38. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ix L.P. Canaan sold 111,498 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $10.01, for a total value of $1,116,094.98. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.